ISRCTN17834262
Completed
Phase 3
A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ethyl lauroyl arginine hydrochloride (ELAH) formulation administered as a nasal spray to reduce viral load in the nasal area in subjects with coronavirus disease 2019 (COVID-19)
Salvacion LLC0 sites30 target enrollmentApril 26, 2022
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19 (SARS-CoV-2 infection)
- Sponsor
- Salvacion LLC
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
2022 Preprint results in https://doi.org/10.21203/rs.3.rs-1432140/v1 (added 09/08/2022)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Signed informed consent
- •2\. Confirmed for Covid\-19 infection by RT\-PCR tests
Exclusion Criteria
- •1\. Allergy to ELAH
- •2\. Females who were breast feeding or lactating
- •3\. History of severe respiratory infections
- •4\. Have received period Covid treatment
- •5\. Participated in any interventional drug trial in previous 30 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study to verify the effectiveness and safety of the modified isothymol or carvacrol compound against SARS-CoV-2 in COVID-19 patientsCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN15363958Instituto Venezolano de Investigaciones Científicas600
Completed
Phase 2
Cediranib maleate with or without gefitinib in treating patients with recurrent or progressive glioblastomaISRCTN00549973niversity College London (UK)38
Completed
Phase 4
Evaluation of Lactosectan versus placebo to compare the effectiveness and safety in treating adult patients with intolerance to certain foods, primarily lactose intoleranceactose intoleranceNutritional, Metabolic, EndocrineLactose intoleranceISRCTN18410689ovintethical Pharma SA60
Completed
Phase 2
stekinumab in adolescents with recent-onset type 1 diabetesType 1 diabetes mellitusNutritional, Metabolic, EndocrineISRCTN14274380Cardiff University88
Completed
Not Applicable
Rifaximin to reduce infection in decompensated cirrhosisDecompensated cirrhosisDigestive SystemISRCTN10994757Imperial College London78